initial public offerings (IPOs) trading on American exchanges

Friday, September 13, 2013

Marrone Bio Innovations (MBII) - profile



Sector: Basic Materials > Industry: Agricultural Chemicals - NEC

Marrone Bio Innovations, Inc. is a provider of bio-based pest management and plant health products. Bio-based products are consists of naturally occurring microorganisms, such as bacteria and fungi, and plant extracts. As of August 1, 2013, the Company’s three commercialized product lines target two core end markets: crop protection and water treatment. Crop protection products consist of herbicides, fungicides, nematicides, insecticides and plant growth regulators that growers use to increase crop yields, improve plant health, manage pest resistance and reduce chemical residues. The Company’s products can be used in both conventional and organic crop production. The Company sells two crop protection product lines, Regalia, for plant disease control and plant health, and Grandevo, for insect and mite control, to growers of specialty crops, such as grapes, citrus, tomatoes, vegetables, nuts, leafy greens and ornamental plants.


Address

Suite A-107, 2121 Second St.
DAVIS, CA 95618
United States
Key stats and ratios
Q1 (Mar '13)2012
Net profit margin-393.74%-543.33%
Operating margin-190.29%-333.87%
EBITD margin--325.28%
Return on average assets-167.05%-177.97%
Return on average equity--
Employees107

Aratana Therapeutics (PETX) : 3-month performance


Sector: Healthcare > Industry: Veterinary Drugs

Aratana Therapeutics, Inc. is a development-stage biopharmaceutical company. As of March 20, 2013, the Company has three licensed compounds in development for six product approvals in cats and dogs in each of the United States and Europe. The Company is developing several compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence, and licensed non-opioid local anesthetic for treating post-operative pain. The company is actively identifying additional programs to in-license from human health companies in order to expand its development pipeline of animal medicines.


Address

1901 Olathe Blvd
KANSAS CITY, KS 66103
United States 

Website links 

http://www.aratana.com

Key stats and ratios

Q1 (Mar '13)2012
Net profit margin--
Operating margin--
EBITD margin--
Return on average assets--68.86%
Return on average equity--
Employees16

Thursday, September 12, 2013

Twitter says it filed confidential IPO registration with U.S. Securities and Exchange Commission


  • Twitter to list on the NYSE on November 15, 2013


(Reuters) - Twitter Inc has filed for an initial public offering with U.S. regulators, the company said on Thursday, taking the first step toward what would be Silicon Valley's most anticipated debut since Facebook Inc's last year.

The impending IPO of the microblogging phenomenon ignited a competition among Wall Street's biggest names for the prestige of managing its coming-out party. Goldman Sachs is lead underwriter, a source familiar with the matter said on Thursday, which is a major coup for the Wall Street bank.

Twitter filed for an IPO confidentially under a 2012 law intended to help emerging corporations with less than $1 billion in revenue go public.


Its debut, though much smaller than Facebook's, could generate tens of millions of dollars in fees from the underwriting mandate itself. Assuming it sells around 10 percent of its shares, or $1 billion, underwriters could stand to divide a fee pool of $40 million to $50 million, assuming an overall fee cut of 4 percent to 5 percent, according to Freeman & Co.

But the benefits for banks that underwrite the deal would likely be far-reaching.

"Some companies will say, ‘We liked the way you handled Twitter, and we want to come to you first when we do our IPO,'" said David Menlow, president of IPOFinancial.com.

"It's not only bragging rights," Menlow said. "It's getting through the front door, which will line up banks for other transactions done after that, like debt financings and M&A."

Technology bankers at major banks from JPMorgan and Credit Suisse Group AG to Morgan Stanley had vied for coveted lead underwriting roles in the IPO. Several have had informal conversations with the micro-blogging network's management, sources familiar with the matter said.

A similar race is on around China's Alibaba, which is expected to raise more than $15 billion this year. Bank chief executives such as JPMorgan's Jamie Dimon and Citigroup Inc's Michael Corbat have made it a point to meet Alibaba founder Jack Ma.

PHENOM

Seven-year old Twitter, which allows users to send out streams of 140-character messages, has become an indispensable tool to governments, corporations and celebrities seeking to communicate with their audience, and for individuals seeking both news and entertainment.

Twitter, which has been valued by private investors at more than $10 billion, is on track to post $583 million in revenue in 2013, according to advertising consultancy eMarketer.

Max Wolff of Greencrest Capital estimated that Twitter would reach break-even this year, and that it is on track for 40 percent annual growth at a $1 billion annual revenue run rate.

"It's completely conquered mobile. It has an enormous social network. It's becoming a key utility as a second screen to TV and it's literally the first draft of history," Wolff said. "Normally a company like Twitter would have been public for some time."

Twitter is allowed to file its registration statement confidentially due to the Jumpstart Our Business Startups (JOBS) Act, a 2012 law that loosened some of the regulations surrounding the IPO process and other forms of capital raising.

Companies that file under that law do not have to reveal certain details until 21 days before embarking on an investor roadshow.

It could allow Twitter to avoid some of the harsh public scrutiny that other tech companies such as Groupon Inc faced. Groupon in 2011 was plagued by questions about its reliance on what some considered to be unusual accounting practices.